Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 159-167 , May 2011

The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes

Received 22 December 2009 ,Revised 5 June 2010 ,Accepted 23 June 2010.

References 

  1. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation. 2002;106:2533–2536
  2. Barkai L, Kempler P. Puberty as a risk factor for diabetic neuropathy. Diabetes Care. 2000;23:1044–1045
  3. Bilal N, Erdogan M, Ozbek M, Cetinkalp S, Karadeniz M, Ozgen AG, et al. Increasing severity of cardiac autonomic neuropathy is associated with increasing prevalence of nephropathy, retinopathy, and peripheral neuropathy in Turkish type 2 diabetics. Journal of Diabetes and its Complications. 2008;22:181–185
  4. Boulton AJ. Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy. European Association for the Study of Diabetes, Neurodiab. Diabetes Metab. 1998;24(Suppl 3):55–65
  5. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. American Diabetes Association. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care. 2005;28:956–962
  6. Cardone C, Painsco P, Marchetti G, Burelli F, Feruglio M, Fedele D. Cough test to assess cardiovascular autonomic neuropathy reflexes in diabetes. Diabetes Care. 1990;13:719–724
  7. Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: The Fremantle Diabetes Study. Diabetologia. 2008;51:562–566
  8. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Annals of Internal Medicine. 1995;122:561–568
  9. Ekberg K, Johansson BL. Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes. Experimental Diabetes Research. 2008;2008:457–912
  10. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985;8:491–498
  11. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine. 2003;348:383–393
  12. Gerritsen J, Dekker JM, TenVoorde BJ, Kostense PJ, Heine RJ, Bouter LM, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: The Hoorn Study. Diabetes Care. 2001;24:1793–1798
  13. González-Clemente JM, Mauricio D, Richart C, Broch M, Caixàs A, Megia A, et al. Diabetic neuropathy is associated with activation of the TNF-α system in subjects with type 1 diabetes mellitus. Clinical Endocrinology (Oxf). 2005;63:525–529
  14. Gottsater A, Ahmed M, Fennlund P, Sundkvist G. Autonomic neuropathy in Type 2 diabetic patients is associated with hyperinsulinaemia and hypertriglyceridaemia. Diabetic Medicine. 1999;16:49–54
  15. Istenes I, Keresztes K, Herm nyi Z, Putz Z, Vargha P, Gandhi R, et al. Relationship between autonomic neuropathy and hypertension—are we underestimating the problem?. Diabetic Medicine. 2008;25:863–866
  16. Karjalainen J, Salmela P, Ilonen J, Surcel HM, Knip M. A comparison of childhood and adult type I diabetes mellitus. New England Journal of Medicine. 1989;320:881–886
  17. Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: The EURODIAB IDDM Complications Study. Diabetic Medicine. 2002;19:900–909
  18. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International. 2005;67:2089–2100
  19. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Management of high blood pressure in children and adolescents: Recommendations of the European Society of Hypertension. Journal of Hypertension. 2009;27:1719–1742
  20. Maser R, Mitchell BD, Vinik AI, Freeman RSO. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: A meta-analysis. Diabetes Care. 2003;26:1895–1901
  21. Matsuki A, Nozawa T, Igarashi N, Sobajima M, Ohori T, Suzuki T, et al. Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress. Circulation Journal. 2010;74:468–475
  22. Muscelli E, Emdin M, Natali A, Pratali L, Camastra S, Gastaldelli A, et al. Autonomic and hemodynamic responses to insulin in lean and obese humans. Journal of Clinical Endocrinology and Metabolism. 1998;83:2084–2090
  23. Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation. 2009;119:2886–2893
  24. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—The EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370–378
  25. Shinozaki N, Yuasa T, Takata S. Cigarette smoking augments sympathetic nerve activity in patients with coronary heart disease. International Heart Journal. 2008;49:261–272
  26. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: The EURODIAB Prospective Complications Study. Diabetes Care. 2004;27:530–537
  27. Sosenko JM, Boulton AJ, Kubrusly DB, Weintraub JK, Skyler JS. The vibratory perception threshold in young diabetic patients: associations with glycemia and puberty. Diabetes Care. 1985;8:605–607
  28. Tentolouris N, Katsilambros N, Papazachos G, Papadogiannis D, Linos A, Stamboulis E, et al. Corrected QT interval in relation to the severity of diabetic autonomic neuropathy. European Journal of Clinical Investigation. 1997;27:1049–1054
  29. Tentolouris N, Grapsas E, Stambulis E, Papageorgiou K, Katsilambros N. Impact of body mass on autonomic function in persons with type 2 diabetes. Diabetes Res Clin Pract. 1999;46:29–33
  30. Tentolouris N, Pagoni S, Tzonou A, Katsilambros N. Peripheral neuropathy does not invariably coexist with autonomic neuropathy in diabetes mellitus. European Journal of Internal Medicine. 2001;12:20–27
  31. Tentolouris N, Liatis S, Moyssakis I, Tsapogas P, Psallas M, Diakoumopoulou E, et al. Aortic distensibility is reduced in subjects with type 2 diabetes and cardiac autonomic neuropathy. European Journal of Clinical Investigation. 2003;33:1075–1083
  32. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. New England Journal of Medicine. 2005;352:341–350
  33. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329:977–986
  34. United Kingdom Prospective Diabetes Study Group (UKPDS 38). Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes. Lancet. 1998;353:837–853
  35. Valensi P, Huard JP, Giroux C, Attali JR. Factors involved in cardiac autonomic neuropathy in diabetes. Journal of Diabetes and its Complications. 1997;11:180–187
  36. Valensi P, Paries J, Attali JR French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: Influence of diabetes duration, obesity and microangiopathic complications—the French multicentre study. Metabolism. 2003;52:815–820
  37. Veves A, Uccioli L, Manes C, Van Acker K, Komninou H, Philippides P, et al. Comparison of risk factors for foot problems in diabetic patients attending teaching hospital outpatient clinics in four different European states. Diabetic Medicine. 1994;11:709–713
  38. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–1579
  39. Vinik AI, Vinik E. Prevention of the complications of diabetes. American Journal of Managed Care. 2003;9(3 Suppl):S63–S80
  40. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387–397
  41. Wieling W, van Brederode JF, de Rijk LG, Borst C, Dunning AJ. Reflex control of heart rate in normal subjects in relation to age: a data base for cardiac vagal neuropathy. Diabetologia. 1982;22:163–166
  42. Wieling W, Schatz IJ. The consensus statement on the definition of orthostatic hypotension: A revisit after 13 years. Journal of Hypertension. 2009;27:935–938
  43. Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH for the EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005;48:164–171
  44. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58:1634–1640
  45. Ziegler D, Cicmir I, Wiefels K, Berger H, Gries FA. Peripheral and autonomic nerve function in long-term insulin-dependent diabetes. Diabetes Research. 1987;4:9–14
  46. Ziegler D, Gries FA, Mühlen H, Rathmann W, Spüler M, Lessmann F. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabetes & Metabolism. 1993;19(1 Pt2):143–151

PII: S1056-8727(10)00066-8

doi: 10.1016/j.jdiacomp.2010.06.001

Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 159-167 , May 2011

Article Tools